TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00706641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100 mg administered orally once daily for 4 weeks duration (+/- 1 week)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Radical cystectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered Dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
Study: NCT02192645

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
Study: NCT01996514

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose with water
Description: Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose with water
Description: Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal
Study: NCT02688985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
Study: NCT01996514

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-caloric sweetener with water
Description: 0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal
Study: NCT04541043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefecon 16mg daily
Description: All study patients received Nefecon 16 mg daily for 9 months.
Study: NCT02927990

Intervention type: OTHER
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention according to standard of care

Intervention type: OTHER
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention according to standard of care
Study: NCT03031613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP group
Description: Application of 5cmH20 positive end expiratory pressure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ZEEP group
Description: No application of positive end expiratory pressure
Study: NCT02373176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PRC 4016 (Icosabutate)
Description: Single oral dose
Study: NCT00026559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock Device
Description: Shock Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Startle Device
Description: Auditory Startle Device
Study: NCT02546193

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
Study: NCT00539305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel
Description: 50-100mg applied topically daily for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: applied topically daily for six months
Study: NCT00711971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPA-rich fish oil supplement
Description: 1060 mg EPA plus 274 mg DHA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich fish oil supplement
Description: 900 mg DHA plus 180 mg EPA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: control arm
Study: NCT01104727

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4-Ports Cholecystectomy (4PC)
Description: a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Port Cholecystectomy (SPC)
Description: a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones.
Study: NCT04312347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen dose adjustment
Description: Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
Study: NCT01177189

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamins C, E, and alpha lipoic acid
Description: Oral antioxidant cocktail or placebo to be consumed daily

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamins C, E, and alpha lipoic acid
Description: Oral antioxidant cocktail or placebo to be consumed daily
Study: NCT03908359

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional cataract surgery
Description: ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimal invasive lens surgery
Description: We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
Study: NCT00550381

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HKI-357
Description: Single-dose capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HKI-357
Description: Single-dose capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HKI-357
Description: Single-dose capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HKI-357
Description: Single-dose capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HKI-357
Description: Single-dose capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HKI-357
Description: Single-dose capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HKI-357
Description: Single-dose capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HKI-357
Description: Single-dose capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HKI-357
Description: Single-dose capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HKI-357
Description: Single-dose capsule
Study: NCT01711450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Description: Injection of local anaesthesia into paravertebral space to provide analgesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control sham procedure
Description: Injection of Normal saline into the paravertebral space
Study: NCT02229929

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A: Placebo
Description: Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: CR845 0.5 mcg/kg
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: CR845 1.0 mcg/kg
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: CR845 2.5 mcg/kg
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part B: Placebo
Description: Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: CR845 1.0 mcg/kg
Description: Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
Study: NCT00793325

Intervention type: DRUG
Intervention: Somatropin
Description: Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.  Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route.
Study: NCT02751476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of Use (PoU) water treatment flocculent disinfectant.
Description: A household level point of use water treatment of a flocculent disinfectant will be tested.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of Use (PoU) water treatment chlorine disinfectant
Description: A household level point of use water treatment of a chlorine disinfectant will be tested.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of Use (PoU) ceramic water filter
Description: A household level point of use water treatment of a ceramic water filter will be tested.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Severe Acute Malnutrition Treatment
Description: Standard CMAM treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Severe Acute Malnutrition Treatment
Description: Standard CMAM treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Severe Acute Malnutrition Treatment
Description: Standard CMAM treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Severe Acute Malnutrition Treatment
Description: Standard CMAM treatment.
Study: NCT00390039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Morphine
Description: MNS075 7.5mg q1h PRN

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IN Placebo q1h PRN

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine
Description: IV morphine 7.5mg q3h PRN
Study: NCT02546193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
Study: NCT03217565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Tedizolid Phosphate
Description: A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Tedizolid Phosphate
Description: A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Tedizolid Phosphate
Description: A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Tedizolid Phosphate
Description: A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Tedizolid Phosphate
Description: A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Tedizolid Phosphate
Description: A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Suspension Tedizolid Phosphate
Description: A single dose of tedizolid phosphate administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Suspension Tedizolid Phosphate
Description: A single dose of tedizolid phosphate administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Suspension Tedizolid Phosphate
Description: A single dose of tedizolid phosphate administered as an oral suspension.
Study: NCT04152200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered by subcutaneous (SC) injection.
Study: NCT05642689

Intervention type: OTHER
Group type: OTHER
Intervention: Iron fortified milk with iron salt labelled with 58Fe and 57Fe
Description: Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.

Intervention type: OTHER
Group type: OTHER
Intervention: Iron fortified milk with iron salt labelled with 58Fe and 57Fe
Description: Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
Study: NCT03518996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS/iTBS/tACS
Description: Subjects with delirium and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS/tACS
Description: Subjects with delirium and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
Study: NCT02063802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid
Description: total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy habits program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy habits program
Study: NCT01996514

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-caloric sweetener with water
Description: 0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV program with non-food advertisements while feeding
Description: 30 minutes of TV program containing non-food ads during a meal
Study: NCT02063802

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy habits program
Study: NCT04160884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green Injection through Peripheral Vein
Description: After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Injection through Peripheral Vein
Description: After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
Study: NCT02978300

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV/HFNC
Description: Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
Study: NCT01996514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV program with non-food advertisements while feeding
Description: 30 minutes of TV program containing non-food ads during a meal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV program with food advertisements while feeding
Description: 30 minutes of TV program containing non-food ads during a meal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV program with food advertisements while feeding
Description: 30 minutes of TV program containing non-food ads during a meal
Study: NCT02962999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: After induction, patients will be received 1 mg/kg ketamine bolus, then administered 0,5 mg/kg/hour ketamine infusion intraoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively.
Study: NCT03188458

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 \[approximately 4-8 weeks of age\]).
Study: NCT03993002

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normoxia with Normocarbia
Description: PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 30-40

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normoxia with Hypercarbia
Description: PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 50-60

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia with Normocarbia
Description: PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 30-40

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia with Hypercarbia
Description: PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 50-60
Study: NCT03154424

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: External fixation in treatment the distal radius fracture
Description: Compare two techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External fixation in treatment the distal radius fracture
Description: Compare two techniques
Study: NCT00490828

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone
Study: NCT02103400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Exercise Training Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Exercise control group
Study: NCT01041742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid loading
Description: fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
Study: NCT03264560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Description: A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychiatry
Description: A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
Study: NCT01860456

Intervention type: DRUG
Intervention: Imatinib/Nilotinib
Description: Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral